Trial to Evaluate AR1001 in Participants with Early Alzheimer's Disease (H-53973)
Description
Content
A Phase III Double-Blind Multi-Center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants with Early Alzheimer's Disease
This trial will test the drug AR1001 in persons 50-90 years old with early Alzheimer's disease. AR1001 is an oral drug that is approved for a medical indication in South Korea and is being tested for efficacy in AD to slow cognitive decline.
Contact
Phone 1: 713–798–6581
IRB: H-53973
Status:
Active
Created:
